Whan In Pharm Co.,Ltd.

KSE 016580.KS

Whan In Pharm Co.,Ltd. Capital Expenditure for the year ending December 31, 2023: USD -24.18 M

Whan In Pharm Co.,Ltd. Capital Expenditure is USD -24.18 M for the year ending December 31, 2023, a 54.82% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Whan In Pharm Co.,Ltd. Capital Expenditure for the year ending December 31, 2022 was USD -53.53 M, a -1,243.00% change year over year.
Whan In Pharm Co.,Ltd. Capital Expenditure for the year ending December 31, 2021 was USD -3.99 M, a 47.20% change year over year.
Whan In Pharm Co.,Ltd. Capital Expenditure for the year ending December 31, 2020 was USD -7.55 M, a -190.46% change year over year.
Whan In Pharm Co.,Ltd. Capital Expenditure for the year ending December 31, 2019 was USD -2.60 M, a 36.68% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

KSE: 016580.KS

Whan In Pharm Co.,Ltd.

CEO	Mr. Wonbum Lee
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	Whanin Building, 11
Employees	582
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Personal Care

Description

Whan In Pharm Co.,Ltd., a pharmaceutical company, develops, manufactures, markets, and sells therapeutic products in South Korea. It offers anti-depressants, anti-psychotics, nootropics and anti-dementia, anti-epileptics, cardiovascular, gastrointestinal, antibiotics, antiviral agents, antihistamines, anti-inflammatory and analgesics, metabolic disorders, respiratory, central nervous system, other drug products. The company was founded in 1978 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years